A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
Abstract: ALK fusion genes are diverse. Approximately 30 different ALK fusion protein partners have been described previously, and some of these fusion proteins have been reported to be effective against ALK-tyrosine kinase inhibitor (TKI). ALK rearrangements often occur at a common breakpoint in exon 20 of the genome. SLC8A1-ALK, a novel fusion protein partner, comes from exon 2 of the SLC8A1 gene rearranged with exon 20 of the ALK gene. Here, we reported a patient with advanced lung adenocarcinoma harboring a SLC8A1-ALK fusion who benefited from first-line treatment with alectinib. After 2 months of taking alectinib, the targeted lung lesions and intrahepatic metastases regressed significantly. To date, the patient has achieved nearly 1 year of progression-free survival while taking the drug. Given the diversity of ALK fusion genes and the different efficacy of ALK-TKIs, we believe that this case report has an important clinical reference.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report ; volume:17 ; number:1 ; year:2022 ; pages:846-850 ; extent:5
Open life sciences ; 17, Heft 1 (2022), 846-850 (gesamt 5)
- Urheber
-
Deng, Ling
Tian, Panwen
Qiu, Zhixin
Wang, Ke
Li, Yalun
- DOI
-
10.1515/biol-2022-0090
- URN
-
urn:nbn:de:101:1-2022081214030941899205
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Deng, Ling
- Tian, Panwen
- Qiu, Zhixin
- Wang, Ke
- Li, Yalun